Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer

World Journal of Urology

Volumn 33, Issue 1, 2015, Pages 105-110

  de Martino, Michela ^a   Shariat, Shahrokh F ^a   Hofbauer, Sebastian L ^a   Lucca, Ilaria ^a   Taus, Christopher ^a   Wiener, Helene G ^a   Haitel, Andrea ^a   Susani, Martin ^a   Klatte, Tobias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aurora; Biomarker; Cystoscopy; Cytology; Diagnosis; Urinary marker

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; MESSENGER RNA;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; URINARY BLADDER NEOPLASMS; URINE; UROTHELIUM;

ADULT; AGED; AURORA KINASE A; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84894100191     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1267-8     Document Type: Article

References (30)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781
2. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27:295–300
3. Karaoglu I, van der Heijden AG, Witjes JA (2013) The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol. doi:10.1007/s00345-013-1035-1 (epub ahead of print)
4. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Drager BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI (2013) ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63:4–15
5. Horstmann M, Bontrup H, Hennenlotter J, Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A, Bruning T (2010) Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 28:399–404
6. Horstmann M, Todenhofer T, Hennenlotter J, Aufderklamm S, Mischinger J, Kuehs U, Gakis G, Stenzl A, Schwentner C (2013) Influence of age on false positive rates of urine-based tumor markers. World J Urol 31:935–940
7. Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ (2012) Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol 30:869–873
8. Tan LB, Chen KT, Yuan YC, Liao PC, Guo HR (2010) Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J Urol 28:117–122
9. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S (2004) Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25:1631–1639
10. Yamamoto Y, Matsuyama H, Kawauchi S, Furuya T, Liu XP, Ikemoto K, Oga A, Naito K, Sasaki K (2006) Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 12:2752–2758
11. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36:55–62
12. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320–1329
13. Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Herrmann FR (2006) Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 32:439–444
14. Bufo P, Sanguedolce F, Tortorella S, Cormio L, Carrieri G, Pannone G (2010) Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histol Histopathol 25:1371–1377
15. Lei Y, Yan S, Ming-De L, Na L, Rui-Fa H (2011) Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem 113:514–518
16. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B (2008) Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 100:1401–1411
17. Compérat E, Bieche I, Dargere D, Laurendeau I, Vieillefond A, Benoit G, Vidaud M, Camparo P, Capron F, Verret C, Cussenot O, Bedossa P, Paradis V (2008) Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology 72:873–877
18. Compérat E, Camparo P, Haus R, Chartier-Kastler E, Radenen B, Richard F, Capron F, Paradis V (2007) Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 450:419–424
19. Koss LG, Melamed MR (2006) Koss’ diagnostic cytology and its histopathologic bases, vol 1. Lippincott Williams & Wilkins, Philadelphia, pp 738–777
20. Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, Van Der Keur KA, Tjin S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ (2013) Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol 64:41–47
21. Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601–1609
22. Mazzorana M, Montoya G, Mortuza GB (2011) The centrosome: a target for cancer therapy. Curr Cancer Drug Targets 11:600–612
23. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr, Golemis EA (2013) Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 70:661–687
24. Meraldi P, Honda R, Nigg EA (2002) Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53 −/− cells. EMBO J 21:483–492
25. Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ (2012) Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol 12:23–28
26. Lotan Y, Shariat SF, Schmitz-Drager BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stohr B, Bassi PF, Grossman HB (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441–448
27. Mhawech-Fauceglia P, Fischer G, Alvarez V Jr, Ahmed A, Herrmann FR (2007) Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int 100:1182–1187
28. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653
29. Faba OR, Palou J, Breda A, Villavicencio H (2012) High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol 30:833–840
30. Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE (2013) The investigational aurora kinase a inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 19:1717–1728